Daniela Rogoff's Colleagues at QED Therapeutics
Daniela Rogoff's Contact Details
HQ
650-231-4088
650-231-4088
Location
United States
United States
Company
QED Therapeutics
QED Therapeutics
Daniela Rogoff's Company Details
QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders. Our lead candidate is infigratinib, a best-in-class FGFR kinase inhibitor that has shown meaningful clinical activity in chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions. QED is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia. We plan to develop infigratinib in additional FGFR-driven tumor types and rare disorders.
Frequently Asked Questions about Daniela Rogoff
Daniela Rogoff currently works for QED Therapeutics.
Daniela Rogoff's role at QED Therapeutics is VP of Clinical Development.
Daniela Rogoff's email address is ***@qedtx.com. To view Daniela Rogoff's full email address, please signup to ConnectPlex.
Daniela Rogoff works in the Research industry.
Daniela Rogoff's colleagues at QED Therapeutics are Elizabeth Freas, Hao Wang, Francesca Avogadri-Connors, Hiywot Takkele, Sherry Markle, Sudesh Kamath, Mag Sellakumaran and others.
Daniela Rogoff's phone number is 650-231-4088